Relaps Multiple Myelom Hastasında Solid Tümör Metastazını Taklit Eden Karaciğer Plazmasitomu: Olgu Sunumu ve Literatürün Gözden Geçirilmesi

Yıl 2022, Cilt: 1 Sayı: 2, 103 - 106, 27.09.2022

Elçin Erdoğan Yücel , Boran Yavuz , Aylin Fatma Karataş , İnci Alacacıoğlu , Sermin Özkal , Oğuz Diçle , Mustafa Seçil , Hayri Özsan

Öz

Amaç: Multiple Myelom (MM) hastalarında sağ kalım uzadıkça, ekstramedüller hastalık görülme sıklığı artmaktadır. Nadir olarak, malign klonlar gastrointestinal sistemi infiltre edebilir. Nodüler hepatik plazmasitom, solid tümör ile karışabilen nadir bir durumdur. Relaps myelom hastasında multiple noduler hepatik plazmasitom saptadığımız ilginç bir vakayı sunuyoruz. Olgu: Myelom hastalarında karaciğer enzimlerinde artış izlendiğinde, plazmasitom da ayırıcı tanılarımız arasında yer almalıdır. Sonuçlar: Bu vaka sunumu ile myelomun ekstramedüller tutulumlarını vurgulamayı amaçladık.

Anahtar Kelimeler

Multiple Myelom, Plazmasitom, Metastaz

Destekleyen Kurum

yok

Liver Plasmacytoma Mimicking Solid Tumor Metastasis in a Relapsed Myeloma Patient: Case Report and Review of the Literature

Öz

Aim: The prevalence of extramedullary disease increases as the survival of Multiple Myeloma (MM) patients prolong. Rarely, malign clones may involve the gastrointestinal system. Nodular hepatic plasmacytoma is also rare and can be confused with solid tumor metastasis. Here we present an interesting case of multiple nodular hepatic plasmacytoma in relapsed myeloma patient. Case: The diagnosis is confirmed by magnetic resonance imaging and trucut biopsy of liver. If elevated liver enzymes are detected in a patient with myeloma, the patient should be evaluated for liver plasmacytoma. In case of doubt, imaging and biopsy should be performed.  Conclusion: We aim to draw attention to the findings of extramedullary involvement in MM patients.

Anahtar Kelimeler

Multiple Myeloma, Plasmacytoma, Metastasis

Kaynakça

• 1.SEER Cancer Stat Facts: Myeloma. National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/statfacts/ html/mulmy.html (accessed Nov 2018).
• 2.Blade J. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29:3805-12.
• 3.Gagelmann N, Eikema DJ, Iacobelli S, Koster L, Nahi H, Stoppa AM et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the chronic malignancies working party of the EBMT. Haematologica. 2018;103:890-7.
• 4. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, pr esenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21:325-30.
• 5.Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97:1761-7.
• 6.Deng S, Xu Y, An G, Sui W, Zou D, Zhao Y et al. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases. Clin Lymphoma Myeloma Leuk. 2015;15:286-91.
• 7.Dhakal A, Chandra A. A Multiple Myeloma Patient Presenting with Multiple Hepatic Masses. Journal Of Medical Cases. 2013;4:673-5.
• 8.Billecke L, Murga Penas EM, May AM, Engelhardt M, Nagler A, Leiba M et al. Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol. 2013;161:87-94.
• 9.Varga C, Xie W, Laubach J, Ghobrial IM, O'Donnell EK, Weinstock M et al. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide- bortezomib combinations. Br J Haematol. 2015;169:843-50.
• 10.Lu YY, Chen JH, Lin WY, Liang JA, Wang HY, Tsai SC et al. FDG PET or PET/CT for detecting intramedullary and extramedullary lesions in multiple myeloma: a systematic review and meta-analysis. Clin Nucl Med. 2012;37:833-7.
• 11.Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015;33:657-64.